Overview of Adverse Events Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
International Blood Research & Reviews,
Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a novel immunotherapy that has shown remarkable success in the treatment of adult relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma, adult R/R mantle cell lymphoma, and R/R acute paediatric lymphoblastic leukaemia. One barrier to the widespread use of CAR T-cell therapy is toxicity, primarily cytokine release syndrome (CRS) with a variable grade of severity. The main manifestations of CRS are fever, hypotension, cytopenia, organ dysfunction among others. Neurological toxicities vary widely and range from headaches to encephalopathy. In addition, anti-CD19 CAR T-cell therapy provokes an array of less frequent events, such as coagulopathies, delayed cytopenia, and cardiovascular toxicities. In general, toxicities are usually reversible and resolve on their own in most cases, though severe cases may require intensive care and immunosuppressive therapy. Deaths due to CRS, neurologic toxicity and infectious complications have been reported, which highlights the gravity of these syndromes and the critical nature of appropriate intervention. In this paper, we look at all available FDA- and EMA-approved information about the pathophysiology, clinical manifestations, risk factor reviews of existing toxicity grading systems, current management strategies, and guidelines for anti-CD19 CAR T-cell toxicities. We also present new approaches, which are under investigation, to mitigate these adverse events.
- CAR T-cells
- chimeric antigen receptor T cells
- cytokine release syndrome
- central nervous system toxicity
- adverse events
How to Cite
Yanagi Y, Yoshikai Y, Leggett K, Clark SP, et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature. 1984;308:145–149.
Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993 Jan 15;90(2):720-4.
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–76. [PubMed: 23546520]
Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013 Apr;3(4):388-98.
Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer. 2003;3:35–45.
DOI: 10.1038/nrc971;pmid: 12509765
Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–398.
Garfall AL, Maus MV, Wei-Ting Hwang SF, Lacey et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. New Engl. J. Med. 2015;373:1040–1047.
Grupp SA, Michael Kalos D, Barrett R, Aplenc David L, Porter et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New Engl. J. Med. 2013;368:1509–1518.
Neelapu SS, Frederick L. Locke, Bartlett NL, Lekakis LJ, Miklos DB, Caron A et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl. J. Med. 2017;377: 2531–2544.
Lee DW, Lee DW, Kochenderfer JN, Stetler-Stevenson M, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose escalation trial. Lancet. 2015;385:517–528.
Brentjens RJ, Marco L Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G Cowell, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013 Mar 20;5(177):177ra38.
FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. Available:https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. United States Food and Drug Administration Press ReleaseAugust 30, 2017.
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma: Yescarta is the second gene therapy product approved in the U.S Available:https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm. United States Food and Drug Administration Press ReleaseOctober 18, 2017.
FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. Available:https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm. United States Food and Drug Administration Press Release May 1, 2018.
Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y. Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132:91.
FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL.
Available: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-relapsed-or-refractory-mcl. United States Food and Drug Administration Press Release July 24, 2020.
FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma.
Available:https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma. United States Food and Drug Administration Press Release February 05, 2021
Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol, abstract 7505.
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.
Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, et al. Cytokine release syndrome. Journal for Immuno Therapy of Cancer. 2018;6:56-70.
Matthys P, Dillen C, Proost P, Heremans H, Van Damme J, Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol. 1993;23:2209–16.
Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-70.
Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro-and anti-inflammatory properties of the cytokine interleukin 6. Biochim. Biophys. 2011;1813:878–888.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448–57.
Kang S, Tanaka T, Inoue H, et al. IL-6 trans-signalling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA. 2020;117(36):22351-22356.
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016 (6):664-679.
Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood;2017.
Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel [published correction appears in J Hematol Oncol. 2018;11:81]. J Hematol Oncol. 2018;11:35. Medline, Google Scholar.
Lee DW, Santomasso BD, Locke FL, Armin Ghobadi, Cameron J Turtle et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47-62.
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.
Schuster SJ, Bishop MR, Tam C, et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-Cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel. Blood. 2018;132: 1684.
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20: 31–42.
M. Wang, J. Munoz, A. Goy, F.L. Locke et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:1331-42.
Maude SL, Laetsch TW, Buechner J, S. Rives, M. Boyer et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439-448.
BREYANZI® (lisocabtagene maraleucel) FDA, full prescribing information. Available:https://www.fda.gov/media/145711/download
Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705-714. Published 2020 Aug 4. doi:10.2147/TCRM.S223468
Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
39] Chen F, Teachey DT, Pequignot E, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods. 2016;434:1–8.
Sun Y, Wang F, Zhao L, zhang B et al. IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell. OncoTargets and Therapy. 2019;12 4907–4925.
Kevin A. Hay. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor‐modified (CAR‐) T cell therapy. British Journal of Haematology. 2018;183:364–374. first published: 08 November 2018.
43] Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017 Dec;7(12):1404-1419.
Barbara Camisa, Giulia Barbiera et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018 Jun;24(6):739-748.
Singh, N., Hofmann, T.J., Gershenson, Z., et al. Monocyte lineage derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy. 2017 July;19(7):867–880. DOI:10.1016/j.jcyt.2017.04.001.
Sattva S. Neelapu. Managing the toxicities of CAR T‐cell therapy. Hematological Oncology. 2019;37(S1):48–52. Published: 12 June 2019.
Stephen J. Schuster MD, Michael R. Bishop et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019;380:45-56.
Bianca D. Santomasso, Jae H. Park, Darin Salloum et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018 Aug;8(8):958-971.
Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in non-human primates. Cancer Discov. 2018;8:750–63.
David Sermer and Renier Brentjens. CAR T-cell therapy: Full speed ahead. Hematological Oncology. 2019;37(S1):95–100. Published 12 June 2019.
Jin Z, Xiang R, Qing K, Kai Qing et al. The severe cytokine release syndrome in phase I trials of CD19‐CAR‐T cell therapy: a systemic review. Ann Hematol. 2018;97:1327‐1335. PMID: 29766234
Jorge Garcia Borrega, Philipp Gödel, Maria Adele Rüger et al. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere. 2019 Apr;3(2):e191. DOI: 10.1097/HS9.0000000000000191.
Frederick L Locke Sattva S Neelapu , Nancy L Bartlett et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan 4;25(1):285-295.
Jennifer N Brudno and James N Kochenderfer. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002.
EMEA. Summary of Product Characteristics, Yescarta. s.l. :
Hamza Hashmi, Abu-Sayeef Mirza, Alicia Darwin et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020;4(17): 4086–4090.
La Rosee, Paul, Paul La Rosée, AnnaCarin Horne, Melissa Hines et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adult. Blood. 2019;133(23):2465–2477. https://doi.org/10.1182/blood.2018894618
Kitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4 (13):3024 - 3033.
Ying Wang, Kunming Qi, Hai Cheng et al. Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. Biol Blood Marrow Transplant. 2020 May;26(5):865-875.
Kitsada Wudhikarn, M. Lia Palomba, Martina Pennisi et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal. 2020;10:Article number: 79.
Cesar Clavijo Simbaqueba, Maria Patarroyo Aponte, Peter Kim et al. Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. J Immunother Precis Oncol. 2020;3:113–120.
Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322-3331. DOI: 10.1182/blood-2017-02-769208.
Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449-459.
Fry TJ, Shah NN, Orentas RJ et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med;2017. DOI:https://doi.org/10.1038/nm.4441.
Gattinoni L, Finkelstein SE, Klebanoff CA et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907–12.
Klebanoff CA, Khong HT, Antony PA et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111–7.
Kochenderfer JN, Yu Z, Frasheri D et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116:3875–86.
Turtle CJ, Hay KA, Gust J et al. Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells. J Clin Oncol. 2017;35:3020. DOI: 10.1200/JCO.2017.35.15_suppl.302
Abramson JS, Lia Palomba M, Leo I Gordon, Lunning MA, Wang Ml, Jon Arnason et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.
Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management Blood Rev. 2019 March;34:45–55.
Turtle CJ, Hanafi LA, Berger C et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–38.
Wang Y, Zhang WY, Han QW et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155:160–75.
Rouce RH, Heslop HE. Forecasting cytokine storms with new predictive biomarkers. Cancer Discov. 2016;6:579–80.
Park JH, Santomasso B, Riviere I et al. Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2017;35:7024. DOI:10.1200/JCO.2017.35.15_SUPPL.7024
Park JH, Riviere I, Wang XY et al. Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2016;34:7003.
Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019 Jul 3;11(499):eaau5907.
Abstract View: 127 times
PDF Download: 40 times